Knee Injuries Clinical Trial
— KNEEXOOfficial title:
A Phase II Trial to Investigate Clinical Efficacy of Autologous Synovial Fluid Mesenchymal Stem Cell-Derived Exosome Application in Patients With Degenerative Meniscal Injury
NCT number | NCT05261360 |
Other study ID # | 56733164/203 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | March 2022 |
Est. completion date | March 2025 |
Comparison of intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes with synovial fluid-derived mesenchymal stem cells on the same patient.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | March 2025 |
Est. primary completion date | March 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 50 Years |
Eligibility | Inclusion Criteria: - Accepting the Informed Consent Form - Degenerative meniscus damage grade 1, 2 or 3 on MRI in both right and left knees, and also the patient does not want surgical treatment - Patients with the same degenerative meniscus grade in both knees - Patients with ongoing pain - Patients without a history of malignancy - Absence of signs of unstable meniscus tear such as snagging or locking - Patients with stage 0, 1 or 2 gonarthrosis according to Kellgren-Lawrence gonarthrosis staging - Patients without lower extremity malalignment Exclusion Criteria: - Patients whose treatment method was explained and who did not accept the method - Patients outside the working-age range - Congenital lesion - Patients requiring surgical treatment (e.g. bucket handle tear and locked knee) - Active inflammatory or connective tissue disease is thought to affect the patient's pain (eg lupus, rheumatoid arthritis, fibromyalgia) - Local or systemic infection - Pregnant or breastfeeding women - Active endocrine disorder that may affect the assessment of patient's pain (eg, hypothyroidism, diabetes) - Active neurological disorder that may affect the assessment of the patient's pain (eg, peripheral neuropathy, multiple sclerosis) - Active heart disease - Presence of a pacemaker - Conditions where MR-I is contraindicated - Patients with stage 3 or 4 gonarthrosis according to Kellgren-Lawrence gonarthrosis staging - Patients with lower extremity malalignment - Patients with signs of unstable meniscus tear such as snagging or locking |
Country | Name | City | State |
---|---|---|---|
Turkey | Eskisehir Osmangazi University | Eskisehir |
Lead Sponsor | Collaborator |
---|---|
Eskisehir Osmangazi University | The Scientific and Technological Research Council of Turkey |
Turkey,
Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. — View Citation
Pan H, Zhang P, Zhang Z, Yang Q. Arthroscopic partial meniscectomy combined with medical exercise therapy versus isolated medical exercise therapy for degenerative meniscal tear: A meta-analysis of randomized controlled trials. Int J Surg. 2020 Jul;79:222-232. doi: 10.1016/j.ijsu.2020.05.035. Epub 2020 Jun 6. Review. — View Citation
Tegner Y, Lysholm J. Rating systems in the evaluation of knee ligament injuries. Clin Orthop Relat Res. 1985 Sep;(198):43-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of Knee Functions | The functional evaluation of the participants will be evaluated on the Tegner-Lysholm knee scoring scale. In Tegner-Lysholm knee scoring, examinations for the knee joint (Limp, support, pain, instability, locking, swelling, stair-climbing, and squatting) will be evaluated, and a maximum of 100 and a minimum of 0 points will be given. According to the evaluation, <65 points are interpreted as bad, 65-83 points as fair, 84-90 points as good, >90 points as excellent. Scores will be recorded by being examined before treatment and at the 6th, and 12th months after treatment. Knee functions of the control group will be evaluated simultaneously, and the effects of treatments on knee function will be determined. | Up to 12th months | |
Primary | Evaluation of Physical Activity | The physical activity evaluation of the participants will be evaluated with the IPAQ (international physical activity questionnaire) short form. IPAQ short form will be evaluated and recorded before treatment and at the 6th, and 12th months after treatment. The control group's physical activity will be evaluated simultaneously, and the effects of treatments on physical activity will be determined. | Up to 12th months | |
Primary | Evaluation of Pain | Pain assessment of the participants will be evaluated with VAS (Visual analog scale). The VAS will be evaluated and recorded before treatment and at the 6th, and 12th months after treatment. The physical activity of the control group will be evaluated simultaneously, and the effects of treatments on pain will be determined. | Up to 12th months | |
Primary | Evaluation of Radiological Images | Participants will receive knee x-ray imaging and knee magnetic resonance imaging before treatment. The same radiological imaging will be performed at the 6th and 12th months after the treatment. At the same time, the same radiological imaging will be performed on the control group, and the effects of treatments on radiological imaging will be evaluated. | Up to 12th months | |
Primary | Evaluation of Cytokine Levels and Cytokine Genes Analyzes | Before treatment and at the 6th and 12th months after treatment, cytokine levels (IL-10, IL-6, TNF-a, IL-8, IL-1ß, IFN-?, IL-2, IL-4, IL-13, MCP-1, VEGF) and gene analyzes (IL-10, IL-6, TNF-a, IL-8, IL-1ß, IFN-?, IL-2, IL-4, IL-13, MCP-1, IL-1ra, MIP-1b, CTGF, TGFß3, BMP-2, BMP-4, IGF-1, IGF-2, PDGF, EGF, and VEGF genes) will be checked in the samples taken from the synovial fluid and blood. Samples will be taken from the control group along with the treatment group. In this way, the effects of treatments on cytokine levels will be evaluated. | Up to 12th months | |
Primary | Evaluation of Edema | Edema in both knees will be measured using a tape measure by marking the midpoints of both patellae. Pre-treatment measurements will be recorded. Measurements of both knees will be recorded at 6 months and 12 months after treatment. The knees of the patients not receiving treatment will be measured simultaneously, and the changes will be compared. | Up to 12th months | |
Primary | Evaluation of Knee Joint Range of Motion | The range of motion of both knees will be measured using the "Baseline Digital Absolute+Axis Goniometer." Knee extension measurements will be made with the patient in the supine position and flexion in the prone position. Pre-treatment measurements will be recorded. Post-treatment 6th and 12th-month measurements will also be recorded. Measurements of patients not receiving treatment will be recorded simultaneously, and changes will be compared. | Up to 12th months | |
Primary | Monitoring of treatment-related complications | Adverse effects and complications will be observed in the treatment group, except for the expected local reactions (redness, swelling, bruising, etc.) after the application. | Up to 12th months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04554212 -
Blood Flow Restriction Training After Patellar INStability
|
N/A | |
Completed |
NCT04815980 -
Impact of Pilates on Running Mechanics
|
N/A | |
Not yet recruiting |
NCT05484778 -
Analysis of Balance and Functional Hop Tests Used for Return to Sports in Athletes With Lower Extremity Injuries by Dual Task Study
|
N/A | |
Terminated |
NCT02909257 -
Motor-Sparing Femoral Nerve Block Dose
|
Phase 4 | |
Completed |
NCT02540811 -
Clinical Evaluation of dCELL® ACL Scaffold for Reconstruction of the Anterior Cruciate Ligament
|
N/A | |
Recruiting |
NCT03755388 -
Clinical Trial of an MRI Based Patient Specific Focal Knee Resurfacing Implant
|
N/A | |
Recruiting |
NCT00174213 -
Validity and Reliability in Measuring Iliotibial Tract by Using Ultrasound
|
Phase 1 | |
Completed |
NCT03202901 -
Accute Effect of B-Turmactive Both on Mild and Moderate Knee Pain on Healthy Volunteers
|
N/A | |
Completed |
NCT06206018 -
Patient-Reported Outcome Measures in Lower Extremity Rehabilitation Program PROM_R: Impact on Health Care
|
N/A | |
Completed |
NCT04543227 -
Opioid Laws and Pediatric Use
|
||
Completed |
NCT06078072 -
Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions
|
||
Completed |
NCT04956393 -
The SOAR (Stop OsteoARthritis) Program Proof-of-Concept Study
|
N/A | |
Recruiting |
NCT06451510 -
Knee Osteoarthritis in the Region of Norrbotten
|
||
Completed |
NCT04118023 -
7T MRI to Evaluate Cartilage Defects in the Knee
|
||
Completed |
NCT03486405 -
A Randomized Control Trial: Returning to Run After Injury
|
N/A | |
Recruiting |
NCT03858231 -
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
|
Phase 4 | |
Recruiting |
NCT02918734 -
Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction. Endobutton vs Metal Interference Screws
|
N/A | |
Suspended |
NCT02270905 -
Clinical Evaluation of dCELL® Meniscus for Partial Replacement of the Meniscus
|
N/A | |
Completed |
NCT01227694 -
Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis
|
Phase 1/Phase 2 | |
Completed |
NCT00991588 -
Clinical Outcome of Posterior Cruciate Ligament (PCL) Posterolateral Reconstruction
|